The antibody - known as LY-CoV1404 or LY3853113 - works by attaching itself to a place on the virus that has shown few signs of mutating, which means the drug is likely to retain its effectiveness over time, the researchers said in a report posted on Friday on bioRxiv ahead of peer review.
Some COVID-19 survivors infected early in the pandemic still have detectable antibodies against the virus a year later, according to a new study.They said vaccination of COVID-19 survivors "would be prudent" because vaccine-induced protection against the virus will likely be more long-lived than antibodies induced by mild COVID-19.
Because early reports had suggested such a link, researchers used the COVID Symptom Study smartphone app to query more than 2.7 million individuals in the United States, the UK and Sweden about their use of aspirin and other NSAIDs, as well as about virus symptoms, COVID-19 testing, and healthcare seeking behavior.
Close to 9,000 participants reported a positive COVID-19 test during the study, according to a report posted on Sunday on medRxiv in advance of peer review.
The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.An experimental monoclonal antibody treatment for COVID-19 being developed by Eli Lilly and Co and AbCellera Biologics Inc can "potently" neutralize numerous coronavirus variants, including those first identified in the UK, Brazil, South Africa, California and New York, scientists have found in test tube experiments.
The antibody - known as LY-CoV1404 or LY3853113 - works by attaching itself to a place on the virus that has shown few signs of mutating, which means the drug is likely to retain its effectiveness over time, the researchers said in a report posted on Friday on bioRxiv ahead of peer review.
UK
Australia
France
Germany
Russia
India
Canada